2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
July 5, 2017Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulatory Filings in Europe — BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 5, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the European Phase 3 ARTEMIS (ARC010) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune’s investigati... 
 
June 20, 2017Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
BRISBANE, Calif. & HELSINKI--(BUSINESS WIRE)--Jun. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the European screening population of the PALISADE trial in Aimmune’s AR101 program. In addition, the company reported observations from a survey on current management and use... 
 
June 15, 2017Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
— Abstracts Report on Screening Population for PALISADE Phase 3 Clinical Trial and Current Management of Peanut Allergy — BRISBANE, California--(BUSINESS WIRE)--Jun. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, announced today that it will present data during poster sessions on Tuesday, June 20, at the 2017 European Academy of Allergy and Clinical Immunolog... 
 
June 12, 2017Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— Final Study Visits Projected Around Year-End 2017; Topline Data Expected in the First Quarter of 2018 — — More Than 97 Percent of Patients Currently On Study Are Through the Up-Dosing Phase — BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 12, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that, in the ongoing Phase 3 PALISADE trial of A... 
 
June 8, 2017Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the Goldman Sachs 38th Annual Global Healthcare conference in Rancho Palos Verdes, California, on Thursday, June 15, at 10:00 a.m. Pacific Time. The live webcast of the presentation will b... 
 
June 7, 2017Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
— Florida Plant Can Produce AR101 for Peanut Allergy for Global Market — BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today hosted a ribbon-cutting ceremony to celebrate the completion of its commercial manufacturing facility in Clearwater, Florida. The facility will produce AR101, Aimmune’s investigational biol... 
 
May 11, 2017Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— “Real-World” Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patient... 
 
May 9, 2017Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
BRISBANE, Calif.--(BUSINESS WIRE)--May 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 16, at 1:00 p.m. Pacific Time. ... 
 
May 8, 2017Aimmune Therapeutics Announces First Quarter 2017 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--May 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for first quarter 2017. As of March 31, 2017, cash, cash equivalents and investments totaled $259.3 million. “We continue to be very pleased with progress in PALISADE, our ... 
 
April 13, 2017Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
— New CFO Is an Established Leader and Healthcare Industry Veteran — BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 13, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer. Mr. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals, Inc., where, over 13 years with the company, his role as CFO expanded to oversee multiple aspects of governance, corporate relations, and other ... 
 
March 15, 2017Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
— Company Began 2017 with Approximately $283 Million in Cash and Investments, Sufficient to Support Current Development Plans through Regulatory Submissions — — Conference Call and Webcast Today at 8:00 a.m. ET — BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food... 
 
March 8, 2017Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
- Conference Call and Webcast to Follow at 8:00 a.m. ET/ 5:00 a.m. PT - BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its financial results for the fourth quarter and full year 2016 will be released on Wednesday, March 15, 2017, before U.S. markets open. At 8:00 a.m. Eastern Time / 5:00 a.m. ... 
 
March 6, 2017Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
— Unique Dataset of Double-Blind, Placebo-Controlled Food Challenges from Phase 3 PALISADE North American Screened Population Is Largest Ever Collected on Peanut-Allergic Patients and Provides Valuable Insights for Future Study — — 95% Adherence to Daily At-Home AR101 Dosing in Blinded Phase 2 Study — BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company develop... 
 
March 1, 2017Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 1, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017, at 10:00 a.m. Eastern Time and at th... 
 
February 27, 2017Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 27, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that new clinical data on AR101 will be presented during poster sessions on Monday, March 6, at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place Mar... 
 
February 16, 2017Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
— AR101 Program to Initially Address Urgent Unmet Need of Peanut-Allergic Patients Ages 4-17, Consistent with Breakthrough Therapy Designation — — Potential BLA Filing to Include Safety Database of 600 Patients, Achievable with Current Phase 3 Program — — Conference Call Today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time — BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 16, 2017-- Aimmune Therapeutics, Inc. (Nasdaq... 
 
January 4, 2017Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation on Wednesday, January 11, 2017, at 5:00 p.m. Pacific Time BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 4, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the 35th Annual J.P. Morgan Healthcare Conferen...